Annual EBIT
-$25.67 M
+$69.14 M+72.92%
31 December 2023
Summary:
Y-mAbs Therapeutics annual earnings before interest & taxes is currently -$25.67 million, with the most recent change of +$69.14 million (+72.92%) on 31 December 2023. During the last 3 years, it has risen by +$94.26 million (+78.60%). YMAB annual EBIT is now -50.67% below its all-time high of -$17.04 million, reached on 31 December 2016.YMAB EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$8.57 M
+$1.22 M+12.47%
30 September 2024
Summary:
Y-mAbs Therapeutics quarterly earnings before interest & taxes is currently -$8.57 million, with the most recent change of +$1.22 million (+12.47%) on 30 September 2024. Over the past year, it has dropped by -$819.00 thousand (-10.57%). YMAB quarterly EBIT is now -125.39% below its all-time high of $33.75 million, reached on 31 March 2021.YMAB Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$28.46 M
-$819.00 K-2.96%
30 September 2024
Summary:
Y-mAbs Therapeutics TTM earnings before interest & taxes is currently -$28.46 million, with the most recent change of -$819.00 thousand (-2.96%) on 30 September 2024. Over the past year, it has dropped by -$4.84 million (-20.48%). YMAB TTM EBIT is now -640.86% below its all-time high of -$3.84 million, reached on 30 September 2017.YMAB TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
YMAB EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +72.9% | -10.6% | -20.5% |
| 3 y3 years | +78.6% | +70.2% | +24.6% |
| 5 y5 years | +40.6% | +64.8% | +61.2% |
YMAB EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +78.6% | -643.1% | +78.5% | -20.5% | +78.5% |
| 5 y | 5 years | at high | +78.6% | -125.4% | +78.8% | -20.5% | +78.5% |
| alltime | all time | -50.7% | +78.6% | -125.4% | +78.8% | -640.9% | +78.5% |
Y-mAbs Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$8.57 M(-12.5%) | -$28.46 M(+3.0%) |
| June 2024 | - | -$9.79 M(+41.7%) | -$27.64 M(+10.2%) |
| Mar 2024 | - | -$6.91 M(+115.9%) | -$25.08 M(-2.3%) |
| Dec 2023 | -$25.67 M(-72.9%) | -$3.20 M(-58.7%) | -$25.67 M(+8.7%) |
| Sept 2023 | - | -$7.75 M(+7.3%) | -$23.63 M(-43.6%) |
| June 2023 | - | -$7.22 M(-3.7%) | -$41.89 M(-43.9%) |
| Mar 2023 | - | -$7.50 M(+550.6%) | -$74.62 M(-21.3%) |
| Dec 2022 | -$94.81 M(+77.5%) | -$1.15 M(-95.6%) | -$94.81 M(-26.7%) |
| Sept 2022 | - | -$26.02 M(-34.9%) | -$129.41 M(-2.0%) |
| June 2022 | - | -$39.95 M(+44.2%) | -$132.10 M(+15.0%) |
| Mar 2022 | - | -$27.70 M(-22.5%) | -$114.87 M(+115.0%) |
| Dec 2021 | -$53.42 M(-55.5%) | -$35.76 M(+24.6%) | -$53.42 M(+41.5%) |
| Sept 2021 | - | -$28.70 M(+26.4%) | -$37.76 M(-9.4%) |
| June 2021 | - | -$22.71 M(-167.3%) | -$41.70 M(-29.8%) |
| Mar 2021 | - | $33.75 M(-268.0%) | -$59.44 M(-50.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | -$119.94 M(+44.5%) | -$20.09 M(-38.4%) | -$119.93 M(-3.0%) |
| Sept 2020 | - | -$32.64 M(-19.3%) | -$123.60 M(+7.2%) |
| June 2020 | - | -$40.45 M(+51.2%) | -$115.32 M(+23.3%) |
| Mar 2020 | - | -$26.75 M(+12.6%) | -$93.50 M(+12.6%) |
| Dec 2019 | -$83.00 M(+92.0%) | -$23.76 M(-2.5%) | -$83.00 M(+13.2%) |
| Sept 2019 | - | -$24.36 M(+30.7%) | -$73.32 M(+21.4%) |
| June 2019 | - | -$18.63 M(+14.6%) | -$60.38 M(+16.1%) |
| Mar 2019 | - | -$16.25 M(+15.4%) | -$52.00 M(+20.3%) |
| Dec 2018 | -$43.23 M(+124.6%) | -$14.08 M(+23.3%) | -$43.23 M(+12.5%) |
| Sept 2018 | - | -$11.41 M(+11.3%) | -$38.43 M(+24.5%) |
| June 2018 | - | -$10.26 M(+37.2%) | -$30.85 M(+49.8%) |
| Mar 2018 | - | -$7.48 M(-19.4%) | -$20.60 M(+57.0%) |
| Dec 2017 | -$19.24 M(+12.9%) | -$9.28 M(+141.4%) | -$13.12 M(+241.4%) |
| Sept 2017 | - | -$3.84 M | -$3.84 M |
| Dec 2016 | -$17.04 M | - | - |
FAQ
- What is Y-mAbs Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics annual EBIT year-on-year change?
- What is Y-mAbs Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics quarterly EBIT year-on-year change?
- What is Y-mAbs Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics TTM EBIT year-on-year change?
What is Y-mAbs Therapeutics annual earnings before interest & taxes?
The current annual EBIT of YMAB is -$25.67 M
What is the all time high annual EBIT for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high annual earnings before interest & taxes is -$17.04 M
What is Y-mAbs Therapeutics annual EBIT year-on-year change?
Over the past year, YMAB annual earnings before interest & taxes has changed by +$69.14 M (+72.92%)
What is Y-mAbs Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of YMAB is -$8.57 M
What is the all time high quarterly EBIT for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high quarterly earnings before interest & taxes is $33.75 M
What is Y-mAbs Therapeutics quarterly EBIT year-on-year change?
Over the past year, YMAB quarterly earnings before interest & taxes has changed by -$819.00 K (-10.57%)
What is Y-mAbs Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of YMAB is -$28.46 M
What is the all time high TTM EBIT for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high TTM earnings before interest & taxes is -$3.84 M
What is Y-mAbs Therapeutics TTM EBIT year-on-year change?
Over the past year, YMAB TTM earnings before interest & taxes has changed by -$4.84 M (-20.48%)